tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Mayank Mamtani, 243 are a BUY (89.34%), 27 are a HOLD (9.93%), 2 are a SELL (0.74%).
Analyst Mayank Mamtani, currently employed at B. RILEY, carries an average stock price target met ratio of 33.03% that have a potential upside of 56.1% achieved within 125 days.
Mayank Mamtani’s has documented 547 price targets and ratings displayed on 43 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on CYTK, Cytokinetics at 21-Jan-2026.
Analyst best performing recommendations are on ARQL (ARQULE).
The best stock recommendation documented was for ALT (ALTIMMUNE) at 11/9/2023. The price target of $8 was fulfilled within 39 days with a profit of $5.55 (226.53%) receiving and performance score of 58.08.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 12-Jul-2023
$12
$8.63 (256.08%)
$12
1 years 4 months 3 days ago
(26-Sep-2024)
0/2 (0%)
$8.93 (290.88%)
Buy
$2.5
$-0.28 (-10.07%)
2 years 11 months 14 days ago
(15-Feb-2023)
1/1 (100%)
$1.86 (290.63%)
145
Buy Since 22-Dec-2021
$30
3 years 7 months 7 days ago
(22-Jun-2022)
0/2 (0%)
$22.32 (290.63%)
Hold Since 02-Sep-2020
$12
$8.63 (256.08%)
5 years 4 months 27 days ago
(02-Sep-2020)
1/2 (50%)
$1.58 (15.16%)
19
Buy Since 31-Aug-2020
5 years 4 months 29 days ago
(31-Aug-2020)
0/1 (0%)
$59.52 (163.16%)
Which stock is Mayank Mamtani is most bullish on?
Which stock is Mayank Mamtani is most reserved on?
What Year was the first public recommendation made by Mayank Mamtani?
